Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03539133

Systemic Organ Communication in STEMI

Despite progress in pre-hospital care, ambulance logistics, pharmacotherapy and PPCI techniques, ST-segment elevation myocardial infarction (STEMI) continues to confer a substantial burden of morbidity and mortality.

Within the STEMI population, there is a spectrum of higher and lower risk patients. The aim of this cohort study is to collect prospectively and systematically clinical research data from STEMI patients. This cohort study is an open-end observational study to identify master switches in myocardial ischemia.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

ST-segment Elevation Myocardial Infarction (STEMI) Anemia Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Artery Disease Coronary Disease Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Heart Diseases Hematologic Diseases Hemic and Lymphatic Diseases Infarction Ischemia Metabolic Diseases Myocardial Infarction Myocardial Ischemia Necrosis Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms ST Elevation Myocardial Infarction Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Division of Cardiology, Pulmonary Disease and Vascular Medicine

Düsseldorf, 40225, Germany

Location status: Recruiting

Location contact

Christian Jung, MD, PhD

CONTACT

Christian Jung, MD, PhD

PRINCIPAL_INVESTIGATOR

Florian Bönner, MD

CONTACT

[email protected]

Malte Kelm, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients suffering from STEMI

Exclusion criteria

  • < 18 years

Treatment and study plan

collection of clinical data

Other

prospectively and systematically collection of clinical research data from STEMI patients

Primary outcomes

  1. Left-ventricular function

    Time frame: 6 months

    • LV-EF < 40% at 6 months
    • Δ LV-EF ≥ 5% between day 5 of hospitalization and 6 months

  2. Left-ventricular remodeling

    Time frame: 6 months

    Δ LVEDV ≥ 20% or Δ LVESV ≥ 15% between day 5 of hospitalization and 6 months

  3. Myocardial texture

    Time frame: on day 5 of hospitalization and 6 months

    • Infarct/Scar size > 17.9% or MVO (yes) or IMH (yes) on day 5 of hospitalization or at 6 months
    • remote zone ΔECV between day 5 of hospitalization and 6 months

  4. Patency rate

    Time frame: 6 months

    Coronary patency rate

Secondary outcomes

  1. All cause mortaltiy

    Time frame: 12 months

    All cause mortaltiy

  2. MACCE

    Time frame: 12 months

    cardiovascular death, non-fatal stroke or myocardial infarction

  3. Re-Hospitalisation due to heart failure

    Time frame: 12 months

    Re-Hospitalisation due to heart failure

Study contacts

Contact information is provided by the study sponsor or research team.

Christian Jung, MD, PhD

CONTACT

[email protected]

+492118118800

Florian Bönner, MD,

CONTACT

[email protected]

+492118118800

Sponsors and collaborators

Lead sponsor

Heinrich-Heine University, Duesseldorf

Other

Registry information

Acronym: SYSTEMI

Important dates

Study start
2017
Primary completion
2030
Study completion
2030
First posted
May 29, 2018
Registry last updated
Jan 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.